U.S. flag

An official website of the United States government, Department of Justice.

NCJRS Virtual Library

The Virtual Library houses over 235,000 criminal justice resources, including all known OJP works.
Click here to search the NCJRS Virtual Library

Prescription Drug Monitoring Program: Delaware State Profile

NCJ Number
Date Published
January 2019
9 pages
Comprehensive information and data are provided for Delaware's Prescription Drug Monitoring Program (PDMP), which is named the "Delaware PMP."
The administering state agency is the Division of Professional Regulation, Office of Controlled Substances, which is a professional licensing agency. The home website address is provided, with extended website addresses for enrollment and queries. Contact information is provided for the PMP Administrator. Statistics for 2017 are reported for the state population (971,180), DEA registered prescribers (5,504), and DEA registered dispensers (222). PDMP available reports are listed. For 2018, funding sources are reported, along with the number of Delaware PMP employees in the following task categories: operational (1), technical (0.5), analytical (1), and "other" (0). Key dates noted for Delaware's PDMP are for authorizing legislation (2010), date it became operational (March 2012), initial user access (August 2012), online access (July 2012), and electronic reporting (March 2012). Statutes and rules that govern the PDMP are noted. Reporting frequency is 1 day. Drugs monitored are controlled substances in schedules II, III, IV, and V, and naloxone administering information. The PMP has the authority to monitor other substances. Opioid-related drug overdoses or deaths are required to be reported by law enforcement agencies and emergency medical services. Miscellaneous capabilities and policies are listed. PDMP enrollment is required for prescribers and dispensers of designated drugs; and as enrollees, they must report the uses for the designated drugs. Law enforcement agencies must report active investigations of the designated drugs and report proper need for the drug upon request. Information is also provided pertinent to PDMP requestor training; technological capabilities; required data transmitters; data collection, storage, generation, and access; interstate data sharing; data integration; patient matching; requestors and reports authorized for generation and being generated.